Last reviewed · How we verify

NCT03986918

Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System

Status unknown Last updated 14 June 2019
What this trial tests

trial testing Routine Total Hip Arthroplasty in Joint Diseases in 400 participants. Status unknown.

Timeline
1 June 2019
Primary endpoint
30 June 2023
30 June 2024

Quick facts

Lead sponsorOrtho Development Corporation
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment400
Start date1 June 2019
Primary completion30 June 2023
Estimated completion30 June 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ortho Development Corporation

Who can join

Adults 18 to 80, any sex, with Joint Diseases or Osteoarthritis, Hip. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate patient outcomes in regards to safety and effectiveness based on the clinical performance of the reference devices to further support the assessment of residual risk identified in the Clinical Evaluation Report for the Ortho Development Hip System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Joint Diseases

Currently open trials in the same condition.

Other Ortho Development Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03986918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing